Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer
YY Syed - Molecular diagnosis & therapy, 2020 - Springer
Abstract Oncotype DX Breast Recurrence Score® is a 21-gene prognostic and predictive
assay indicated for use in patients with hormone receptor-positive, human epidermal growth …
assay indicated for use in patients with hormone receptor-positive, human epidermal growth …
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
R Colomer, I Aranda-López, J Albanell… - Clinical and …, 2018 - Springer
This consensus statement revises and updates the recommendations for biomarkers use in
the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society …
the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society …
Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in …
MC Roberts, DP Miller, S Shak, VI Petkov - Breast cancer research and …, 2017 - Springer
Abstract Purpose The Oncotype DX® Breast Recurrence Score™(RS) assay is validated to
predict breast cancer (BC) recurrence and adjuvant chemotherapy benefit in select patients …
predict breast cancer (BC) recurrence and adjuvant chemotherapy benefit in select patients …
[HTML][HTML] Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
EJ Blok, E Bastiaannet, WB Van den Hout… - Cancer Treatment …, 2018 - Elsevier
Gene expression profiles with prognostic capacities have shown good performance in
multiple clinical trials. However, with multiple assays available and numerous types of …
multiple clinical trials. However, with multiple assays available and numerous types of …
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in …
S Holt, G Bertelli, I Humphreys, W Valentine… - British journal of …, 2013 - nature.com
Background: Tumour gene expression analysis is useful in predicting adjuvant
chemotherapy benefit in early breast cancer patients. This study aims to examine the …
chemotherapy benefit in early breast cancer patients. This study aims to examine the …
[HTML][HTML] Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women …
J Albanell, C Svedman, J Gligorov, SDH Holt… - European Journal of …, 2016 - Elsevier
Abstract Purpose The 21-gene Recurrence Score assay (Oncotype DX) provides
prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer …
prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer …
[HTML][HTML] OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
RC Stein, JA Dunn, JMS Bartlett… - Health Technology …, 2016 - ncbi.nlm.nih.gov
BACKGROUND There is uncertainty about the chemotherapy sensitivity of some oestrogen
receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast …
receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast …
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry
SM Stemmer, M Steiner, S Rizel… - NPJ breast …, 2017 - nature.com
Abstract The 21-gene Recurrence Score®(RS) assay is a validated prognostic/predictive
tool in ER+ early-stage breast cancer. However, clinical outcome data from prospective …
tool in ER+ early-stage breast cancer. However, clinical outcome data from prospective …
The EndoPredict gene-expression assay in clinical practice-performance and impact on clinical decisions
BM Müller, E Keil, A Lehmann, KJ Winzer… - PloS one, 2013 - journals.plos.org
The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients
with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy …
with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy …
[HTML][HTML] Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
S Harnan, P Tappenden, K Cooper… - Health Technology …, 2019 - ncbi.nlm.nih.gov
BACKGROUND Breast cancer and its treatment can have an impact on health-related
quality of life and survival. Tumour profiling tests aim to identify whether or not women need …
quality of life and survival. Tumour profiling tests aim to identify whether or not women need …